<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047857/" ref="ordinalpos=575&amp;ncbi_uid=6241507&amp;link_uid=PMC4047857" image-link="/pmc/articles/PMC4047857/figure/fig5/" class="imagepopup">Figure 5.  From: SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span>. </a></div><br /><div class="p4l_captionBody">SPAG5 regulation influenced mTOR signaling pathway activation in cervical cancer cell lines under taxol treatment. Taxol treatment after SPAG5 downregulation in (<b>a</b>) HeLa and (<b>b</b>) SiHa cervical cancer cell lines revealing differing drug sensitivities under different concentrations due to (<b>c</b>) apoptosis. (<b>d</b>) Western blot analysis of mTOR signaling pathway activation</div></div>